Immunitybio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.51
- Today's High:
- $1.785
- Open Price:
- $1.61
- 52W Low:
- $1.21
- 52W High:
- $7.8
- Prev. Close:
- $1.54
- Volume:
- 8780256
Company Statistics
- Market Cap.:
- $698.06 million
- Book Value:
- -1.457
- Revenue TTM:
- $592000
- Operating Margin TTM:
- -62803.89%
- Gross Profit TTM:
- $240000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -76.32%
- Return on Equity TTM:
- 0%
Company Profile
Immunitybio Inc had its IPO on 2015-07-28 under the ticker symbol IBRX.
The company operates in the Healthcare sector and Biotechnology industry. Immunitybio Inc has a staff strength of 683 employees.
Stock update
Shares of Immunitybio Inc opened at $1.61 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.51 - $1.79, and closed at $1.69.
This is a +9.74% increase from the previous day's closing price.
A total volume of 8,780,256 shares were traded at the close of the day’s session.
In the last one week, shares of Immunitybio Inc have increased by +10.46%.
Immunitybio Inc's Key Ratios
Immunitybio Inc has a market cap of $698.06 million, indicating a price to book ratio of 0 and a price to sales ratio of 4822.3335.
In the last 12-months Immunitybio Inc’s revenue was $592000 with a gross profit of $240000 and an EBITDA of $-352710016. The EBITDA ratio measures Immunitybio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Immunitybio Inc’s operating margin was -62803.89% while its return on assets stood at -76.32% with a return of equity of 0%.
In Q2, Immunitybio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 17.1%.
Immunitybio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.05 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immunitybio Inc’s profitability.
Immunitybio Inc stock is trading at a EV to sales ratio of 5498.7312 and a EV to EBITDA ratio of -8.8912. Its price to sales ratio in the trailing 12-months stood at 4822.3335.
Immunitybio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $291.23 million
- Total Liabilities
- $613.48 million
- Operating Cash Flow
- $-8604000.00
- Capital Expenditure
- $8.53 million
- Dividend Payout Ratio
- 0%
Immunitybio Inc ended 2024 with $291.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $291.23 million while shareholder equity stood at $-642116000.00.
Immunitybio Inc ended 2024 with $0 in deferred long-term liabilities, $613.48 million in other current liabilities, 44000.00 in common stock, $-2632710000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $43.51 million and cash and short-term investments were $45.95 million. The company’s total short-term debt was $524,496,000 while long-term debt stood at $250.10 million.
Immunitybio Inc’s total current assets stands at $66.83 million while long-term investments were $841000.00 and short-term investments were $2.45 million. Its net receivables were $3.28 million compared to accounts payable of $25.49 million and inventory worth $13.04 million.
In 2024, Immunitybio Inc's operating cash flow was $-8604000.00 while its capital expenditure stood at $8.53 million.
Comparatively, Immunitybio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.69
- 52-Week High
- $7.8
- 52-Week Low
- $1.21
- Analyst Target Price
- $4.5
Immunitybio Inc stock is currently trading at $1.69 per share. It touched a 52-week high of $7.8 and a 52-week low of $7.8. Analysts tracking the stock have a 12-month average target price of $4.5.
Its 50-day moving average was $2.1 and 200-day moving average was $3.11 The short ratio stood at 8.43 indicating a short percent outstanding of 0%.
Around 7257.9% of the company’s stock are held by insiders while 1066.4% are held by institutions.
Frequently Asked Questions About Immunitybio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.